Company: HCTI
Filing Date: 2025-05-15
Form Type: 424B4
Source: 0001213900-25-044095
Chunk: 11

Company: Healthcare Triangle, Inc.
Filing Date: 2025-05-15
Form: 424B4
Chunk 11
---
 result, we will not be required to adopt new or revised accounting standards on the dates on which adoption of such standards is required for other public reporting companies. We are also a “smaller reporting company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies. Corporate Information We were originally incorporated in Nevada on October 29, 2019, and subsequently converted into a Delaware corporation on April 27, 2020. Our principal executive office is located at 7901 Stoneridge Drive, Suite 220, Pleasanton, CA 94588. Our telephone number is (925) 270-4812. Our website address is https://www.healthcaretriangle.com/. The information on our website or that may be accessed by links on our website is not incorporated by reference into this prospectus.

<div align='center'>3</div>

The Offering

| Issuer:                                              |     | Healthcare Triangle, Inc., a Delaware corporation.                                                                                                                                                                                                                                                                                                                                                                                                             |
| Securities being offered by the Selling Stockholder: |     | Up to 1,483,809,885 shares of Common Stock, consisting of up to                                                                                                                                                                                                                                                                                                                                                                                                
 (i) 7,017,429 shares of Common Stock purchased from us by the selling stockholders as part of units (each a Unit”) pursuant                                                                                                                                                                                                                                                                                                                                    
 to Securities Purchase Agreements (each a “Securities Purchase Agreement”) dated February 27, 2025 between us and the                                                                                                                                                                                                                                                                                                                                          
 applicable selling shareholder; (ii) 29,173,056 shares of Common Stock that may be issued to the selling stockholders if they fully                                                                                                                                                                                                                                                                                                                            
 exercise the pre-funded warrants (the “Pre-funded Warrants”) that were included in the Units; (iii) 361,904,850 shares                                                                                                                                                                                                                                                                                                                                         
 of Common Stock that may be issued to the selling stockholders if they fully exercise the Series A warrants (the “Series A                                                                                                                                                                                                                                                                                                                                     
 Warrants”) that were included in the Units at the floor price of $0.084 per share and (iv) 1,085,714,550 shares of Common Stock                                                                                                                                                                                                                                                                                                                                
 that may be issued to the selling stockholders if they fully exercise the Series B warrants (the “Series B Warrants”                                                                                                                                                                                                                                                                                                                                           
 and together with the Series A Warrants, the “Purchase Warrants”) using